A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancerHenry Gómez, G. W. Sledge, Brian Wood et al.|Journal of Clinical Oncology|2005Cited by 72
Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancerHenry Gómez, Adrián Martín, Miguel A. Chavez et al.|Journal of Clinical Oncology|2007Cited by 11